Amundi
ARQT icon

Amundi’s Arcutis Biotherapeutics ARQT Stock Holding History

Amundi’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$238K Hold
9,091
– – ﹤0.01% 1918
2026
Q1 		$214K Buy
+9,091
New +$232K ﹤0.01% 1857
2025
Q2 		– Sell
-66
Closed -$1.07K – 1689
2025
Q1 		$1.07K Buy
+66
New +$930 ﹤0.01% 2027
2022
Q4 		– Sell
-4,774
Closed -$95K – 1900
2022
Q3 		$95K Hold
4,774
– – ﹤0.01% 1565
2022
Q2 		$114K Buy
+4,774
New +$97.9K ﹤0.01% 1427

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Amundi's ARQT Position: Q2 2026 in Review

Amundi held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 9,091 shares worth $238K. The position accounts for ﹤0.01% of the portfolio, ranked #1918.

Amundi first reported a position in ARQT in Q2 2022 and has held it in 5 quarters since. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Amundi held 9,091 shares of Arcutis Biotherapeutics worth $238K as of Q2 2026.
  • Amundi left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1918 holding.
  • Amundi first reported a position in Arcutis Biotherapeutics in Q2 2022 and has held it in 5 quarters since.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.